Variation in GH and IGF‐I assays limits the applicability of international consensus criteria to local practice
Top Cited Papers
- 27 April 2007
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 67 (1) , 65-70
- https://doi.org/10.1111/j.1365-2265.2007.02836.x
Abstract
There is increasing reliance on consensus criteria for decision making. Recent criteria state that acromegaly is excluded by a nadir GH during an oral glucose tolerance test (OGTT) of < 1 microg/l and a normal level of IGF-I. To study GH and IGF-I assay performance close to cut-off values for active acromegaly. Two serum samples known to give borderline results were sent to all centres participating in the UK National External Quality Assessment Service (NEQAS). Sample A was assigned to be a nadir during an OGTT and sent for GH assessment to 104 centres. Sample B, with a clinical scenario, was sent to 23 centres that measure IGF-I, and these centres were asked to measure IGF-I, interpret the result and provide the source of their reference ranges (RRs). For sample A, the median GH was 2.6 mU/l (range 1.04-3.5 mU/l). Applying a conversion factor (CF) of 2.0 (1 microg/l = 2 mU/l), the most negatively biased method classified 10% of the values consistent with acromegaly, while the most positively biased method classified all values as consistent with the diagnosis. Applying a CF of 3.0 (1 microg/l = 3 mU/l), only 11% of results were consistent with acromegaly. For sample B, the median IGF-I was 50.8 nmol/l (range 24.3-60.9 nmol/l). All centres used age-related RRs. There was a 50% variation in the upper limit of the RRs between centres. Overall, 30% of the IGF-I results were against the diagnosis. There was little agreement in the RRs quoted by centres using the same method. Variability in assay performance, coupled with use of inappropriate CFs and RRs, undermines the applicability of international consensus criteria to local practice.Keywords
This publication has 27 references indexed in Scilit:
- Effect of Sex and Assay Method on Serum Concentrations of Growth Hormone in Patients with Acromegaly and in Healthy ControlsClinical Chemistry, 2006
- Consensus statement: medical management of acromegalyActa Endocrinologica, 2005
- How Robust Are Laboratory Measures of Growth Hormone Status?Hormone Research in Paediatrics, 2005
- The Second International Standard for Somatropin (Recombinant DNA-derived Human Growth Hormone): Preparation and Calibration in an International Collaborative StudyBiologicals, 2001
- Predictors of the Outcome of Surgical Treatment in Acromegaly and the Value of the Mean Growth Hormone Day Curve in Assessing Postoperative Disease ActivityJournal of Clinical Endocrinology & Metabolism, 2001
- Two-Year Follow-Up of Acromegalic Patients Treated with Slow Release Lanreotide (30 mg)Journal of Clinical Endocrinology & Metabolism, 2000
- Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort StudyJournal of Clinical Endocrinology & Metabolism, 1998
- How Much Insulin-Like Growth Factor I (IGF-I) Circulates? Impact of Standardization on IGF-I Assay AccuracyJournal of Clinical Endocrinology & Metabolism, 1998
- Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone DeficiencyJournal of Clinical Endocrinology & Metabolism, 1998
- Development of a simple valid method for the complete removal of insulin-like growth factor (IGF)-binding proteins from IGFs in human serum and other biological fluids: comparison with acid-ethanol treatment and C18 Sep-Pak separationJournal of Clinical Endocrinology & Metabolism, 1995